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Received August 13, 2010; accepted January 12, 2011AbstractBackground: We aimed to establish a feasible and reliable method to measure the level of aripiprazole and its main metabolite, dehydroar-
ipiprazole, using a capillary-electrophoresis (CE) machine.
Methods: Two blood samples were obtained from psychiatric patients hospitalized in Yu-Li Hospital who had been treated with aripiprazole for
more than 4 weeks, at least 10 mg/d. Conditions for voltage, temperature and buffer concentration was optimized on a CE machine.
Results: The most optimal conditions for CE were 80 mM 2e3% DMSO-phosphate as a buffer under pH ¼ 3.0, 15 KV, 20C and a detection
wavelength of 214 nm. The linear ranges of aripiprazole and dehydroaripiprazole concentration were from 0.5 to 50 ng/mL.
Conclusion: CE method is a feasible method to measure aripiprazole level with relatively low price compared with other analytical techniques
for clinical use.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Aripiprazole (Abilify) is an atypical antipsychotic agent,
recently approved by the US Food and Drug Administration as
the sixth second-generation antipsychotic for the treatment of
schizophrenia, schizoaffective disorders, bipolar disorder and
adjuvant therapy for major depression.1 Dehydroaripiprazole,
its main active metabolite, has an affinity for dopamine D2
receptors and thus has some pharmacological activities similar
to that of its parent compound.2,3
Aripiprazole is considered a partial dopamine D2 and D3
receptor agonist, partial 5-HT1A receptor agonist and 5-HT2A* Corresponding author. Dr. Tsuo-Hung Lan, Department of Psychiatry, Tai-
chung Veterans General Hospital, 200, Section 1, Dong-Da Road, Taichung 407,
Taiwan, ROC.
E-mail address: tosafish@hotmail.com (T.-H. Lan).
1726-4901/$ - see front matter Copyright  2011 Elsevier Taiwan LLC and the C
doi:10.1016/j.jcma.2011.04.006receptor antagonist.4e6 The partial agonist activity at the D2
receptor may explain its efficacy in the treatment of both
positive and negative symptoms of schizophrenia and its low
probability for extra-pyramidal symptoms.7 Its side-effects
including weight gain, QTc prolongation and hyper-
prolactinemia. Nevertheless, it is not devoid of side-effects
such as nausea, vomiting, lightheadedness, somnolence, con-
stipation and postural dizziness.8 Monitoring drug concentra-
tions in plasma may not only ensure effectiveness and safety,
but also preclude side-effects, especially for psychiatric
patients with poor communication skills and impaired self-
care. The commonly recommended therapeutic dosage
prescribed for aripiprazole ranges from 10 mg/d to 30 mg/d,
with a starting dose of 10 mg/d or 15 mg/d.7 However, the
relationship between aripiprazole concentration in plasma and
drug effectiveness has not been well established yet.2hinese Medical Association. All rights reserved.
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prazole were mostly confined to high-performance liquid
chromatography (HPLC),9,10 for example, HPLC with photo
diode array detection,10 HPLC-tandem mass spectrometry,11,12
LC-tandem mass spectrometry2,13,14 and ultra-performance
LC-electrospray tandem mass spectrometry.15 The validated
gas chromatography-mass spectrometry (GC-MS) method was
developed in previous study and provides an accurate and
reliable assay for analyzing of aripiprazole and dehydroar-
ipiprazole in blood samples of psychiatric patients.2
Capillary-electrophoresis (CE) is one of the preferred
techniques which has been frequently used in pharmaceutical
quality control as well as clinical chemistry. The device has
relatively high sensitivity, shorter analyzing time, and lower
costs compared with HPLC. Furthermore, the precision of CE
is as good as that of LC, and less effort for sample pre-
treatments is needed in CE. Urine and even plasma can be
directly injected without further pre-treatments.16
CE is used in analyzing and separating several antipsy-
chotics, including zotepine, ziprasidone, clothiapine, cloza-
pine, olanzapine and quetiapine.17e19 There were limited
reports about applying CE in detecting antipsychotics
concentration in human blood.8 CE was also used in detecting
zotepine with solid-phase extraction and binary system of
head-column field-amplified sample stacking method.17 Raggi
used a rapid CE method for the determination of clozapine and
desmethylclozapine in human plasma and it proved to have
good precision.20
Studies on using CE method for analysis of aripiprazole
and its metabolites were limited. Musenga et al.8 reported that
a CE method with dual wavelengths was able to detect ari-
piprazole at 214 nm within 5 minutes (uncoated fused silica
capillaries and a background electrolyte composed of 50 mM
phosphate buffer at pH 2.5, 20 kV). The authors used loxapine
as the internal standard, and the plasma sample was pre-treated
by using solid-phase extraction on cyano cartridges, with
extraction yield rate higher than 91.3%.8 However, there are
different detection modules available for CE. The CE machine
used in the study of Musenga et al.8 were equipped with dual
wavelengths of 214 nm and 590 nm. The study used solid-
phase extraction, a complicated and expensive method, for
sample condensation. In this report, we describe the use of
a liquid extraction method for sample condensation and the P/
ACE MDQ System to detect aripiprazole and its metabolites.
The broader wavelength range of The P/ACE MDQ System,
between 190 nm and 600 nm, provides a more sensitive and
alternative platform for such purpose.
2. Methods2.1. Chemicals and standardsAll reagents were analytical grade chemicals from Merck,
including NaOH, HCl, phosphate, sodium dihydrogenphosphate,
disodium hydrogenphosphate, methanol (MeOH), NaHCO3,
dimethyl sulfoxide (DMSO). Aripiprazole (OPC-14597, Abil-
ify), dehydroaripiprazole (OPC-14857) and the internalstandard (OPC-14714) were obtained from the Otsuka Pharma-
ceutical Co. Ltd. (Tokyo, Japan) as a gift.2.2. Standard mixtureAripiprazole, OPC-14587 and OPC-14714 were dissolved
in DMSO to make 1000 ng/mL solutions. Methanol was added
to the solutions and adjusted to concentration of 200 ng/mL.2.3. Running bufferFour kinds of running buffer were prepared. Sodium
dihydrophosphate (NaH2PO4) was used as a base, and phos-
phate (H3PO4) was added to adjust pH value to be around pH
2.0e4.0 as a phosphate buffer. MeOH and DMSO were then
added to the above phosphate buffer, respectively and pro-
portionally, to make 2.5e20% MeOH-phosphate buffer,
1e10% DMSO-phosphate buffer and MeOH-DMSO-
phosphate buffer.2.4. Blood samples and plasma extractionBlood samples (No.030-205, No.038-205) were obtained
from 2 schizophrenic patients who had been hospitalized in
a psychiatric hospital with aripiprazole administered for more
than 4 weeks, 10 mg/d. Participants who met DSM-IV criteria
for schizophrenia or schizoaffective disorder were diagnosed by
at least two board-certified psychiatrists. For the purpose of
having stabilized plasma level of aripiprazole, patients with the
first episode of illness were excluded and consent forms were
obtained before the experiment began. A 200-mL aliquot of each
patient’s plasma was added to 5 mL of OPC-14714 (IS) (200 ng/
mL). The mixture was then combined with 1 mL NaHCO3 and
extracted with 4 mL diethyl ether and then vortexed for 20
minutes. After mixing, the sample was centrifuged with 1500 g
for 5minutes. The samplewas stored in an80C freezer for 90
minutes. The supernatant was moved into another tube, and
dried by40Cnitrogen gas. The residuewas resolved by 25mL
ofmethanol and 25mL running buffer (v/v, 50:50) with vortex (1
minute). Then, the samplewas transferred to a 0.2-mLmini-vial
which was placed into the sample tray of a Beckman P/ACE
MDQ system for CE analyses.2.5. Instrumentation and capillary conditioningCE machine P/ACE MDQ System (Beckman, CA, USA)
equipped with a photo diode array (PDA) detector which
detected signals over 190e600 nm wavelength was used, and
pH was detected by pH parameter 6,130 (Jenco, San Diego,
CA, USA). The capillary had total length of 60 cm by 75 mm
internal diameter; the capillary activation process was oper-
ated under 25C and pressure of 20 psi. At the beginning of
each day, the capillary was pre-treated by a sequence of
methanol for 10 minutes, 1M HCl for 10 minutes, deionized
water for 5 minutes, 1M NaOH for 10 minutes, deinoized
water for 5 minutes, then running buffer for 10 minutes under
pressure of 20 psi.
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bymeans of our CEmachine, PDA detector was used for finding
the optimal detection wavelength, the optimal voltage (10 kv,
15 kv, 20 kv, 25 kv, 30 kv), the suitable operating temperature
(18C, 20C, 25C) and the suitable running buffer setting under
different solutions: (1) pH 2.0e4.0 phosphate buffer; (2)
2.5e20% MeOH-phosphate buffer; (3)1e10% DMSO-
phosphate buffer; (4) MeOH-DMSO-phosphate, respectively.2.7. Method validationTo evaluate the quantitative application of the method,
a repetition test was performed. The within-day variability test
was repeated 3 times a day with 5 different concentrations of
aripiprazole, OPC-14857 over the range of 10e50 ng/mL and
fixed dose of OPC-14714 (IS) 20 ng/mL were analyzed. The
between-day variability was tested in 8 consecutive days using
50 ng/mL of aripiprazole and OPC-14857.2.8. Statistical methodWe set up a linear regression equation which used the peak
area of internal standard OPC-14714 as its X axis and its
corresponding concentration (ppm) as Y axis, and quantified
the concentration of aripiprazol and OPC-14857 by linear
interpolation method.
The lowest detection range of concentration was based on
the regression curve and its intersection at the Y axis. The
analysis was done by P/ACE MDQ 32 Karat 7.0 software.
3. Results3.1. Determine the optimal conditions for quantifying
aripiprazole
3.1.1. General settings
Using the PDA detector, the strongest signal was found
over wavelength of 214 nm during detection of aripiprazoleFig. 1. The separations of standard in pH ¼ 3, different concentration of DMSO-ph
50 ng/mL, (2) aripiprazole: 50 ng/mL, (3) OPC-14857: 50 ng/mL.and its metabolite OPC-14857. Thus, we thereafter used a 214-
nm filter in ultraviolet/visible spectrophotometry for detection
in the experiment. The greater the voltage, the shorter the
migration time of the standard, and the shorter the peak
distance between standards as well. Standards could be sepa-
rated efficiently at a voltage of 15 kVand got better waveform.
With higher temperature and shorter migration time of stan-
dards, however, the electric current will be increased. There
was no significant difference between 18C and 20C. We
chose 20C as the temperature setting in this experiment for
reducing the cost of Freon.
3.1.2. Optimization of running buffer
Pure phosphate buffer failed to separate aripiprazole from
OPC-14857 under any pH value. We then tried to find out
the influence of percentage of MeOH and DMSO used in the
running buffer. The higher the concentration of MeOH, the
better the waveform of separation. Nevertheless, because of
the high volatility of MeOH, it was not suitable to use more
MeOH in experimental procedures. Ten percent of MeOH-
phosphate buffer was found to have better stability and sepa-
ration of waveform.
Aripiprazole and its active metabolites are weak basic
because of the tertiary amine group. The effect of pH was
tested in 10% MeOH-phosphate buffer, and the separation
curve showed better under pH ¼ 3.0.
We could successfully separate aripiprazole from OPC-
14857 under the concentration between 2.5% and 10%
DMSO-phosphate buffer, but the higher concentration of
DMSO in the buffer, the lower the peak height and area under the
wave of the aripiprazole, OPC-14714 and OPC-14857 were
demonstrated. Furthermore the migration time of analyses was
increased along with increasing concentration of DMSO
(Fig. 1). The migration time difference between 2% and 3%
DMSO-phosphate buffer was not huge, but the integration area
was much more stable under the 3% DMSO-phosphate buffer.
Furthermore, aripiprazole could be separated from OPC-14857
under any concentration proportion of MeOH-DMSO-
phosphate buffer. Thus, we chose 2e3% DMSO-phosphate
buffer under pH 3.0 as the optimal running buffer.osphate buffer: (A) 6% (B) 5% (C) 4% (D) 3% (E) 2% (F) 1% (1) OPC-14714:
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Fig. 2. The calibration line of 2w10 ng/mL aripiprazole by using the standard
OPC-14714 concentrations of 2 ng/mL, 4 ng/mL, 6 ng/mL, 8 ng/mL, 10 ng/
mL, respectively; detection range of aripiprazole: 1.5e10 ng/mL.
Table 2
The within-day variabilities (n ¼ 3), 5 different concentrations of aripiprazole,
OPC-14857 and fixed dose of OPC-14714 (IS) 20 ng/mL
Concentration
known (ng/mL)
Mean concentration
found (ng/mL)
RSD (%) RE (%)
Aripiprazole within-day (n ¼ 3)
10 16.030  3.021 18.84 60.3
20 20.087  0.468 2.33 0.435
30 29.247  0.219 0.75 2.51
40 38.180  0.709 1.86 4.55
50 48.957  0.609 1.24 2.09
OPC-14857 within-day (n ¼ 3)
10 10.963  0.346 3.16 9.63
20 19.843  0.951 4.79 0.79
30 29.650  0.140 0.47 1.17
40 38.310  0.699 1.82 4.23
50 48.940  0.440 0.90 2.12
RE ¼ relative error; RSD ¼ relative standard deviation.
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active metabolite
The calibration curve was used to quantify the concentra-
tion of aripiprzaole and its metabolite OPC-14857. The stan-
dard mixture was prepared by adding aripiprazole, OPC-14587
and OPC-14714 (internal standard) into DMSO; then MeOH
was added to adjust final concentration to 200 ng/mL. The
concentration of standard mixture was adjusted by adding
running buffers of 0.5 ng/mL, 1 ng/mL, 2 ng/mL, 4 ng/mL,
6 ng/mL, 8 ng/mL, 10 ng/mL, 20 ng/mL, 30 ng/mL, 40 ng/mL,
and 50 ng/mL, respectively.
The calibration curve was set up by using the peak area of
the internal standard as its X axis and the concentration of the
internal standards as its Y axis, and then quantifying the
concentration of aripiprazole and OPC-14857 using the linear
interpolation method.
Using the method described above, three calibration curves
was drawn (in concentrations of 10e50 ng/mL, 2e10 ng/mL
(Fig. 2) and 0.5e4 ng/mL) of the aripiprazole and its metab-
olite OPC-14857, respectively. The respective limits of
detection for aripiprazole and OPC-14857 were 1.5 ng/mL and
0.6 ng/mL (Table 1), respectively.3.1.4. Validation of the method
To evaluate the quantitative applicability of the methods, five
different concentrations of aripiprazole and dehydroar-
ipiprazole were analyzed using OPC-14714 as an IS. Except for
one obvious deviation in the third test of 10 ng/mL aripiprazole
showing 21.93 ng/mL, which increased the mean concentration
and RSD (relative standard deviation). Other results in Tables 2
and 3 show that the RSD of within-day and between-day vari-
abilities in different concentrations, from high, mediumelow,Table 1
The respective limits of detection for aripiprazole and OPC-14857
Lowest detection
concentration (ng/mL)
Aripiprazole (ng/mL) OPC-14857 (ng/mL)
Curve 1 (10e50) 4 4
Curve 2 (2e10) 1.5 1.5
Curve 3 (0.5e4) 1.5 0.6were all below 5%. The accuracy of aripiprazole and OPC-
14857, obtained from the RE values at five different concen-
trations, were all below 5% for between-day assays. The results
showed the accuracy of aripiprazole and OPC-14857 concen-
trations were also stable over 8 consecutive days.
3.1.5. Application
Plasma samples of two schizophrenic patients were
condensed into 4 fold by using liquid extraction method for
sample purification and concentration because of the limita-
tion of detection. The recovery rate after liquid extraction was
0.6. It was determined by estimating the concentrations of
internal standard before and after the extraction.
The result of our samples checked from GC-MS method
were A ¼ 523.3 ng/L and B ¼ 655 ng/L. The concentrations
were to A ¼ 1.255 ng/mL and B ¼ 1.572 ng/mL in CE
method, and the real concentrations from CE method were
1.772 ng/mL and 1.432 ng/mL, respectively. Sample A’s
concentration from CE method was higher than expected, but
sample B was lower. The concentrations of the two samples
were both located on the calibration curve.
4. Discussion
CE is a convenient and reliable approach to detect chemical
reagents in different liquid phases such as serum or urine. From
this study, we found the optimal analytic conditions for quan-
tifying the concentrations of aripiprazole and its metabolites.
Futhermore, the method is stable, and its results were repeatable
without obvious error as well. The lowest concentration we
could detect was about 1 ng/mL, the same as the limitation of our
CE machine P/ACE by using PDA detector (Beckman). The
lowest detectable range of CEmethod in our studywas extendedTable 3
The between-day (n ¼ 8) variability, Aripiprazole and OPC-14857 (50 ng/mL)
Mean concentration found (ng/mL) SD RSD (%)
Aripiprazole 45.85 4.10 8.95
OPC-14857 50.46 3.31 6.56
RSD ¼ relative standard deviation; SD ¼ standard deviation.
Table 4
Comparison of different methods for detecting Aripiprazole
Cost Sensitivity Speed Pollution
GC-MS, LC-MS High High Slow High
HPLC Moderate High Slow High
CE Low Moderate Fast Low
CE ¼ capillary-electrophoresis; GC-MS ¼ gas chromatography-mass spec-
trometry; HPLC ¼ high-performance liquid chromatography; LC-MS ¼ liquid
chromatography-tandem mass spectrometry.
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mended therapeutic dose ranges from 10 mg/d to 30 mg/d, with
a starting dose of 5 mg/d to 10 mg/d.21 In our study, both of the
patients were taking aripiprazole 10 mg/d. When applied clin-
ically, plasma concentration might not be necessary because
most patients take more than 10 mg of aripiprazole.
The sensitivity of GC-MS is 1000-fold higher than that of
the CE method. However, the cost of HPLC, LC-tandem mass
spectrometry and GC-MS are much higher than that of CE. By
using CE method, we could save nearly 90% of cost spent in
GC-MS, if the amount of study survey were large. We could
also provide sensitivity enhancement by various approach, for
example, head-column field-amplified sample stacking in
binary system.17 Furthermore, CE will not produce as much
waste and pollutants as HPLC does during the experimental
procedure (Table 4). Both Musenga et al. and our study found
that CE method may be used to detect aripiprazole. Our study
further indicates the lowest limitation of the method, which is
relatively cheaper in concentration the plasma samples.
Monitoring drug plasma concentration in schizophrenia
patients is helpful in the monitoring of existing drug level and
compliance. The validated CE developed in this study provides
a simple, rapid, reproducible, accurate and reliable assay for
quantifying of aripiprazole and dehydroaripiprazole in blood
samples of psychiatric patients and showed better stability in
detection over higher concentrations. Applying the technique
obtained from this study to clinical use could be used as a refer-
ence for monitoring aripiprazole’s therapeutic effect and mini-
mizing side-effects in clinical response. The patients’ compliance
for treatment responses and quality of life would increase.
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